31 studies found for:    ACADIA
Show Display Options
Rank Status Study
1 Active, not recruiting A Pivotal Study of a Facet Replacement System to Treat Spinal Stenosis
Condition: Lumbar Spinal Stenosis
Interventions: Device: ACADIA® Facet Replacement System;   Device: Instrumented posterolateral fusion
2 Recruiting Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children
Conditions: Attention Deficit Hyperactivity Disorder;   Anxiety
Interventions: Dietary Supplement: L. helveticus R0052 and B. longum R0175;   Other: Placebo
3 Active, not recruiting Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression
Conditions: Anxiety;   Depression
Interventions: Other: Probiotics;   Drug: Placebo
4 Completed Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
Condition: Schizophrenia
Intervention: Drug: ACP-103
5 Completed ACP-104 in Acutely Psychotic Subjects With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: ACP-104;   Drug: Placebo
6 Recruiting Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
Condition: Adjunctive Treatment of Major Depressive Disorder
Interventions: Drug: Pimavanserin;   Other: Placebo
7 Recruiting Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)
Condition: Agitation and Aggression in Alzheimer's Disease
Interventions: Drug: Pimavanserin 34 mg;   Drug: Pimavanserin 20 mg;   Other: Placebo
8 Recruiting Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
Condition: Schizophrenia
Interventions: Drug: Pimavanserin;   Drug: Placebo
9 Recruiting Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
Condition: Schizophrenia
Interventions: Drug: Pimavanserin;   Drug: Placebo
10 Approved for marketing Expanded Access of Pimavanserin for Patients With PD Psychosis
Condition: Parkinson's Disease Psychosis
Intervention: Drug: Pimavanserin tartrate
11 Active, not recruiting A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
Condition: Alzheimer's Disease Psychosis
Interventions: Drug: Pimavanserin tartrate;   Drug: Placebo
12 Completed An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
Condition: Parkinson's Disease Psychosis
Intervention: Drug: pimavanserin tartrate (ACP-103)
13 Completed
Has Results
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Condition: Parkinson's Disease Psychosis
Interventions: Drug: pimavanserin tartrate;   Drug: placebo
14 Completed
Has Results
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Condition: Parkinson's Disease Psychosis
Intervention: Drug: Pimavanserin tartrate (ACP-103)
15 Active, not recruiting A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Condition: Parkinson's Disease Psychosis
Intervention: Drug: pimavanserin tartrate (ACP-103)
16 Completed
Has Results
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Condition: Parkinson's Disease Psychosis
Interventions: Drug: Pimavanserin tartrate (ACP-103);   Drug: Placebo
17 Completed Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
Conditions: Hallucinations;   Psychoses;   Parkinson's Disease
Intervention: Drug: ACP-103
18 Completed Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics
Condition: Schizophrenia
Interventions: Drug: ACP-104;   Drug: Placebo
19 Completed A Transformational Teaching Intervention: Adolescents in Motion (AIM) Trial
Condition: Physical Activity
Interventions: Behavioral: Transformational Teaching;   Behavioral: Standard Educational Practices
20 Terminated The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Condition: Cardiovascular Disease
Interventions: Drug: bococizumab (PF-04950615);   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.